EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Pre‐Treatment Serum Ferritin on Response and Survival in Myelodysplastic Syndromes Treated With Azacytidine: A Multivariate Analysis

Gloria Moreno Carrasco, Rodolfo Matias Ortiz Flores iD, Regina García Delgado, Borja Cidoncha Morcillo, Ana Isabel Rosell Mas, Dana Díaz Canales, María Rodríguez González, Manuel Carrasco Gomariz, Alejandro Escamilla-Sánchez iD

Cancer Medicine · 2025

DOI: 10.1002/cam4.71127 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Gloria Moreno Carrasco und 8 weiteren Autor:innen. Beteiligte Einrichtung: UGC Hematología y Hemoterapia, Hospital Universitario Virgen de la Victoria, Málaga, Spain. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Ferritins, Azacitidine, Antimetabolites, Antineoplastic. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Myelodysplastic syndromes (MDS) encompass a heterogeneous group of haematological neoplasms characterized by ineffective haematopoiesis and a variable risk of transformation to acute myeloid leukaemia (AML). Elevated serum ferritin (SF), a marker of iron overload (IO), has been linked to poorer outcomes in MDS. However, the impact of pre‐treatment SF levels on azacytidine (AZA) response and survival outcomes remains unclear.

Methods

This retrospective cohort study included patients with World Health Organization‐defined MDS or AML with 20%–30% bone marrow blasts treated with AZA at the Virgen de la Victoria University Hospital (Málaga, Spain) from 2007 onwards. Patients were stratified into three groups based on pre‐treatment SF levels: < 500 ng/mL, 500–1000 ng/mL and > 1000 ng/mL. Logistic regression and Kaplan–Meier methods were used to analyse overall response (OR) and overall survival (OS).

Results

Among 240 patients, 190 with available SF data were analysed. Patients with SF > 1000 ng/mL showed significantly lower OR (24.2%) and shorter OS (median: 10.1 months) compared to those with SF < 500 ng/mL (OR: 71.4%, OS: 18.2 months) and 500–1000 ng/mL (OR: 82.6%, OS: 20.5 months) ( p < 0.0001 for OR, p = 0.001 for OS). Multivariate analysis confirmed elevated SF as an independent predictor of poorer outcomes.

Conclusions

Elevated pre‐treatment SF levels are strongly associated with reduced response and survival in patients with MDS or AML treated with AZA. Early IO management, such as iron chelation, may improve treatment outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesFerritinsAzacitidineAntimetabolites, AntineoplasticHumansFemaleMaleAgedRetrospective StudiesMiddle AgedAged, 80 and overAdultMultivariate AnalysisTreatment OutcomeKaplan-Meier EstimateLeukemia, Myeloid, AcutePrognosis

Stichwörter der Autor:innen

azacytidineferritinhypomethylating agentsiron overloadmyelodysplastic syndromeoverall survivalprognostic biomarkerretrospective cohort studytransfusion dependencytreatment response

Substanzen

FerritinsAzacitidineAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • UGC Hematología y Hemoterapia, Hospital Universitario Virgen de la Victoria, Málaga, Spain.
  • BE21-Hematología e Inmunoterapia, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Málaga, Spain.
  • Departamento de Fisiología Humana, Histología Humana, Anatomía Patológica y Educación Físico-Deportiva, Facultad de Medicina, Universidad de Málaga, Málaga, Spain.
  • UGC Farmacia, Hospital Universitario Virgen de la Victoria, Málaga, Spain.

ORCID-Profile: Rodolfo Matias Ortiz Flores, Alejandro Escamilla-Sánchez

Zitieren

APA

Carrasco, G. M., Flores, R. M. O., Delgado, R. G., Morcillo, B. C., Rosell Mas, A. I., Díaz Canales, D., González, M. R., Gomariz, M. C., & Escamilla-Sánchez, A. (2025). Impact of Pre‐Treatment Serum Ferritin on Response and Survival in Myelodysplastic Syndromes Treated With Azacytidine: A Multivariate Analysis. Cancer Medicine. https://doi.org/10.1002/cam4.71127

Vancouver

Carrasco GM, Flores RMO, Delgado RG, Morcillo BC, Rosell Mas AI, Díaz Canales D, et al. Impact of Pre‐Treatment Serum Ferritin on Response and Survival in Myelodysplastic Syndromes Treated With Azacytidine: A Multivariate Analysis. Cancer Medicine. 2025. doi:10.1002/cam4.71127

BibTeX
@article{Carrasco2025,
  author = {Carrasco, Gloria Moreno and Flores, Rodolfo Matias Ortiz and Delgado, Regina García and Morcillo, Borja Cidoncha and Rosell Mas, Ana Isabel and Díaz Canales, Dana and González, María Rodríguez and Gomariz, Manuel Carrasco and Escamilla-Sánchez, Alejandro},
  title = {Impact of Pre‐Treatment Serum Ferritin on Response and Survival in Myelodysplastic Syndromes Treated With Azacytidine: A Multivariate Analysis},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71127}
}
Kostenlos starten →